P1111: COMPARATIVE EFFICACY AND SAFETY OF TISAGENLECLEUCEL AND AXICABTAGENE CILOLEUCEL IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA

• M. Dickinson,
• J. Martinez-Lopez,
• E. Jousseaume,
• C. Anjos,
• H. Yang,
• X. Chai,
• T. Wang,
• R. Ramos,
• C. Lobetti-Bodoni,
• S. Schuster,
• N. Fowler

Affiliations

M. Dickinson

1 Peter MacCallum Cancer Centre, Royal Melbourne Hospital and the University of Melbourne, Melbourne, VIC, Australia

J. Martinez-Lopez

2 Hospital Universitario 12 de Octubre, Complutense University, CNIO, Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain

E. Jousseaume

3 Novartis Pharmaceuticals AG, Basel, Switzerland

C. Anjos

4 Novartis Pharmaceuticals Corporation, East Hanover, NJ

H. Yang

5 Analysis Group Inc., Boston, MA

X. Chai

5 Analysis Group Inc., Boston, MA

T. Wang

5 Analysis Group Inc., Boston, MA

R. Ramos

4 Novartis Pharmaceuticals Corporation, East Hanover, NJ

C. Lobetti-Bodoni

3 Novartis Pharmaceuticals AG, Basel, Switzerland

S. Schuster

6 Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

N. Fowler

7 The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America